CEO William Weldon said J&J already tries to use alternatives when possible. The proposal was presented by a representative of People for the Ethical Treatment of Animals, which placed picketers outside the meeting hotel.
Addressing the company’s recently announced plan to acquire medical device-maker Synthes for $21.3 billion, Mr. Weldon said it would give J&J a much bigger share of the market for surgical trauma equipment and orthopedic implants. “It is consistent with our long-term strategy to strengthen our leadership position around the world,” he said.
Addressing a recent string of drug recalls by the company, Mr. Weldon told shareholders Johnson & Johnson will be “stronger than ever.” The company has gutted the factory responsible for most of the recalls and is rebuilding as a state-of-the-art facility to replace it.
Read the San Francisco Chronicle report on Johnson & Johnson.
Related Articles on Medical Supplies:
North Carolina’s Wake Endoscopy Center Selects ProVation MD Software
Johnson & Johnson’s Synthes Takeover May Spur More Orthopedic Deals
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
